NIRMATRELVIR-RITONAVIR EFFECTIVENESS ANALYSIS AND INTERACTION PROFILE ANALYSIS
J.M. CASELLES GIL, C. PUVECINO MORENO, Y. CASTELLANOS CLEMENTE, M. GARCÍA GIL

**BACKGROUND AND IMPORTANCE**

Nirmatrelvir-ritonavir emerged as a new drug with the aim of preventing serious pathology in high-risk patients with COVID.

**AIM AND OBJECTIVES**

To analyze the effectiveness and pharmacological interaction profile of nirmatrelvir-ritonavir in patients diagnosed with SARS-Cov2.

**MATERIALS AND METHODS**

<table>
<thead>
<tr>
<th>WHAT?</th>
<th>WHERE?</th>
<th>WHEN?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Observational and retrospective study</td>
<td>In a second level hospital</td>
<td>January 2022 – August 2022</td>
</tr>
</tbody>
</table>

**WHO?**

Patients diagnosed with mild-moderate SARS-Cov2 for whom treatment with nirmatrelvir-ritonavir was requested.

**PRIMARY EFFECTIVENESS ENDPOINT**

- Hospital admission or death from any cause through day 28.

**SECONDARY VARIABLE**

- Profile of pharmacological interactions and its management.

**HOW?**

Data was obtained from the electronic medical record and the pharmacy dispensing program. Descriptive statistical analysis was performed using Excel® 16.48. The results of main questions were compared with the results of the pivotal EPIC-HR.

**RESULTS**

- 86 patients were included. 37 (43.02%) did not receive treatment. Sample of 49 patients.
- Mean age was 67.5 years (SD=16) and 25 (51.02%) of them were men.

**EFFECTIVENESS**

Hospital-admission or death was registered in 16/49 patients (32.65%): 14 events were hospital-admission (28.57%) and 2 deaths (4.08%).

**SAFETY**

We detected 77 interactions in 39/49 (79.59%) patients [2.14 interactions/patient; SD=1.42]. Mainly with statins 14/77 (18.17%), metamizole 9/77 (11.68%). Management: monitor 55/77 (71.43%), suspend treatment and reintroduce it 3 days after 20/77 (25.98%) and reduce the dose 2/77 (2.59%).

**CONCLUSIONS AND RELEVANCE**

It seems that the real-life results of nirmatrelvir-ritonavir are inferior to those obtained in the pivotal RCT, mainly due to the higher number of hospital admissions. Most of the patients presented interactions, which could be managed in a simple way through temporary suspension and monitoring.